Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Lexicon Pharmaceuticals, Inc.

News headline image
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Announces Proposed Public Offering of Common Stock
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.